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an increased volume of EF and a dysfunctional 
profile of gene expression in this fat depot.4 More­
over, major differences were found in the gene 
expression of inflammatory markers in both EF 
and pericardial fat (PF) depots.4 The glucagon­
­like peptide ­1 (GLP ­1) is an incretin hormone 
with a spectrum of pharmacological and meta­
bolic effects: an increase in glucose ­dependent 
INTROduCTION Epicardial fat (EF) is a visceral 
adipose tissue depot surrounding coronary ar­
teries that has the unique embryology, anato­
my, and functionality.1 The increased volume of 
EF was found to be a risk factor for cardiovascu­
lar diseases.2,3 As we described previously, among 
patients with advanced coronary artery disease 
(CAD), type 2 diabetes (T2D) was associated with 
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INTROduCTION The expression of glucagon ‑like peptide receptors (GLP ‑Rs) in epicardial fat (EF) and 
pericardial fat (PF) depots might be involved in the pathogenesis of cardiovascular diseases.
ObjECTIvEs We sought to evaluate the messenger RNA (mRNA) expressions of GLP ‑1R and GLP ‑2R 
in EF and PF and their associations with the renin ‑angiotensin ‑aldosterone system (RAAS) in patients 
with multivessel coronary artery disease (CAD).
PATIENTs ANd mEThOds Consecutive stable patients with multivessel CAD requiring elective coronary 
artery bypass grafting were enrolled. Clinical data, anthropometric parameters, and the quantity of fat depots 
(assessed by cardiovascular magnetic resonance and abdominal ultrasound) were obtained. Fat samples 
(EF, PF, subcutaneous fat) were taken from patients during cardiac surgery. Relative mRNA expression 
of GLP ‑1R, GLP ‑2R, and RAAS components (angiotensin II receptor type 1, angiotensinogen, angioten‑
sin I–converting enzyme 1, and angiotensin I–converting enzyme 2) were assessed in those fat depots.
REsuLTs Fifty ‑three patients (64.7 [7.4] years) were included in the final analysis. We found that only the 
relative expression of GLP ‑2R was lower in PF compared with subcutaneous fat (reference). Ultrasound 
abdominal fat depots were associated with both GLP ‑1R and GLP ‑2R in PF. GLP ‑1R and GLP ‑2R showed 
significant correlations with RAAS components in both EF and PF.
CONCLusIONs In stable patients with multivessel CAD, the relative mRNA expression for both GLP 
receptors was significantly associated with the majority of the analyzed RAAS components.
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anti ­infective medicines in prior month, second­
ary causes of obesity, specific interventions aimed 
at obesity, unintentional weight loss or malnutri­
tion, and contraindications to CMR.
The study was approved by the local Med­
ical University of Silesia Ethics Committee 
(KNW/0022/KB1/127/I/13/14) and all indi­
viduals gave their written informed consent to 
the protocol.
Clinical characteristics Cardiovascular diseas­
es and risk factors were defined according to 
the European Society of Cardiology guidelines14 
and identified based on prior diagnosis and / or 
current treatment. Type 2 diabetes was deter­
mined based on fasting plasma glucose levels of 
126 mg/dl or greater, and / or glycated hemoglobin 
of 6.5% or greater, or current antidiabetic treat­
ment.15 All medical records and medications used 
were determined by a physician using a structured 
medical questionnaire.
ultrasound measurements Ultrasound (GE Viv­
id 9, Milwaukee, Wisconsin, United States) was 
used in all patients to assess the abdominal sub­
cutaneous (7.5 MHz transducer) or visceral (3.5 
MHz transducer) fat depots. As described before, 
the following ultrasound measures were obtained: 
abdominal subcutaneous fat (ASF), abdominal 
preperitoneal fat thickness (APFT), and visceral 
intra ­abdominal thickness (IAT).16,17 The following 
ratios were used to assess the relative amounts of 
visceral adipose tissue depots and cardiovascular 
risk. To demonstrate the association between IAT 
to ASF and APFT to ASF, we calculated the IAT to 
ASF and APFT to ASF ratios.
Cardiac magnetic resonance imaging of epicardial 
and pericardial fat Prior to sample collection, 
the EF and PF volumes were quantified on elec­
trocardiography­gated cine images acquired on 
a 1.5 T system (GE Optima MR450w, GE Health­
care, Waukesha, Wisconsin, United States) with 
a dedicated cardiac coil using a steady ­state free 
precession sequence. EF and PF were identified as 
the adipose tissue depot in end diastole (EF, be­
tween myocardium and visceral layer of pericardi­
um; PF, all the fat surrounding the heart outside 
EF) along the walls of the right and left ventricles 
starting from the basal segments (atrioventricu­
lar valves level) up to the apex area. Particular fat 
volumes were traced manually and calculated us­
ing the summation of disc method with the scan 
parameters as described previously.4
Fat tissue collection The fat tissue samples were 
taken at the beginning of the CABG procedure 
from tissues that had not been traumatized. All 
the samples were taken in the same order and 
locations in all patients: 1) SF at sternotomy, 
2) PF within the thorax, and 3) EF adjacent to 
the proximal right coronary artery. The biopsy 
specimens were immediately stored at –80 °C un­
til further analysis.
insulin secretion and in natriuresis and diuresis, a 
decrease in glucagon production and gastric emp­
tying, and therefore, inhibition of food intake.5-7 
Recently, a large clinical trial showed a significant 
reduction of cardiovascular mortality in patients 
with T2D and high cardiovascular risk by one of 
glucagon ­like peptide­1 analogues, which could 
be partly associated with targeting GLP ­1R.8,9 
The expressions of GLP ­1R or GLP ­2R in fat de­
pots and their relation to the renin ­angiotensin­
­aldosterone system (RAAS) are unknown. There­
fore, we sought to determine the mRNA expres­
sion of GLP ­1R and GLP ­2R in EF and PF depots 
obtained from patients with multivessel CAD. 
Furthermore, we hypothesized that mRNA ex­
pression of both GLP ­1R and ­2R would be asso­
ciated with RAAS components.
PATIENTs ANd mEThOds study population Study 
patients were screened and recruited at the De­
partment of Cardiology and the Department of 
Cardiac Surgery of the Medical University of Sile­
sia in Katowice. A total of 56 consecutive patients 
with chronic coronary syndromes scheduled for 
elective coronary artery bypass grafting (CABG) 
were included in the study and finally 53 were in­
cluded in the study group. Three patients did not 
complete the protocol (change in the treatment 
schedule) and were excluded from further anal­
ysis. The study protocol and methods were de­
scribed in details in our previous paper.4 Briefly, 
the study included clinical assessment, anthropo­
metric parameters, quantification of various fat 
depots in ultrasound and cardiovascular magnetic 
resonance (CMR), and fat samples obtained dur­
ing cardiac surgery. All patients had standardized 
pharmacotherapy according to the current Euro­
pean Society of Cardiology guidelines.10-13
The main exclusion criteria were defined as fol­
lows: acute coronary syndrome, congestive heart 
failure, left or right ventricular systolic dysfunc­
tion, indications for any other type of cardiac sur­
gery, infectious or chronic inflammatory diseases 
in prior 2 months, neoplastic diseases (diagnosis 
and / or treatment in prior 5 years), significant re­
nal or liver dysfunction, any anti ­inflammatory or 
whAT’s NEw?
The expression of glucagon ‑like receptors (GLP ‑R) in epicardial fat (EF) and 
pericardial fat (PF) depots might be involved in the pathogenesis of cardio‑
vascular diseases. The aim of the present study was to evaluate the relative 
expression of GLP ‑1R and GLP ‑2R messenger RNA (mRNA) in EF and PF and 
their associations with the renin ‑angiotensin ‑aldosterone system (RAAS). 
First, the expression of GLP receptor mRNA was present in EF and PF. To our 
knowledge, this is the first study to demonstrate that the expression of GLP ‑1R 
and GLP ‑2R mRNA was associated with RAAS components. Moreover, in 
patients with coronary artery disease, RAAS components were expressed in 
EF. Additionally, the expression of GLP ‑2R was lower in PF as compared with 
subcutaneous fat. Finally, we found that ultrasound visceral fat ratios were 
also associated with GLP ‑1 and GLP ‑2 receptors.
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statistical analysis The results are expressed as 
means (SD) for normally distributed variables, 
medians (interquartile ranges [IQRs]) for non­
­normal distribution, or numbers (percentages). 
The distribution was tested for the normality with 
the Kolmogorov–Smirnov test. Baseline clinical 
parameters and the measures were compared be­
tween the subgroups using the paired t tests for 
normally distributed continuous variables; in case 
of non ­normal distribution, the Wilcoxon rank 
sum test was used. Associations between param­
eters (genes expressions obtained from the for­
mula 2(­ΔΔCt)) were assessed using the Pearson or 
Spearman rank correlation analysis depending on 
normal and non ­normal data distribution, and 
are shown as r and R correlation coefficients, re­
spectively. The relative mRNA expressions were 
described as medians and 95% CIs. A P value of 
less than 0.05 was considered statistically signif­
icant. Statistical analysis was performed using 
the Statistica software (version 10.0, Stat Soft, 
Kraków, Poland).
REsuLTs study group characteristics The final 
analysis included 53 patients (mean [SD] age, 
64.7 [7.4] years; 75% men) with multivessel CAD 
requiring CABG and multiple cardiovascular risk 
factors (mean [SD], 5.5 [1.4]). In brief, all patients 
had hypertension and dyslipidemia. The majori­
ty of the study group were overweight (53%) or 
obese (39%), and almost half of them (49%) had 
T2D (TAbLE 1). All patients had preserved left ven­
tricular ejection fraction (mean [SD], 55.3% [4%]) 
and no other primary cardiomyopathy, which was 
evidenced in CMR. All patients received guideline­
­based pharmacotherapy including acetylsalicyl­
ic acid, angiotensin ­converting enzyme inhibi­
tor or angiotensin II receptor blocker, β ­blocker, 
and statin (TAbLE 1). Treatment of T2D was also 
specified in TAbLE 1.
Glucagon -like peptide receptors and fat depots 
GLP ­1R relative mRNA expression was compa­
rable in PF (median, 0.747; 95% CI, 0.268–1.348) 
and EF (median, 0.364; 95% CI, 0.088–0.947) 
when compared with SF (FIGuRE 1A). Contrary, 
GLP ­2R expression was decreased in PF (median, 
0.167; 95% CI, 0.098–0.329) bot not in EF (me­
dian, 0.412; 95% CI, 0.28–1.018) when compared 
with SF expression (FIGuRE 1b). Relative mRNA ex­
pression of GLP ­1R and GLP ­2R between both 
fat depots (PF and EF) were similar (P = 0.17 and 
P = 0.07, respectively). We observed significant 
associations between both GLP receptors in PF 
(R = 0.6; P <0.0001) and EF (R = 0.4; P <0.01). 
However, there were no differences in mRNA ex­
pression of both GLP receptors when patients 
with T2D were compared with those without T2D 
and patient with BMI of 30 or greater with those 
with BMI less than 30 kg/m2 (data not shown).
Glucagon -like peptide receptors and fat depot vol-
ume on cardiovascular magnetic resonance There 
were no associations between the expression of 
RNA extraction and reverse transcription–poly-
merase chain reaction RNA was extracted us­
ing the phenol ­chloroform method using the 
TRI Reagent (MRC Inc., Cincinnati, Ohio, Unit­
ed States).18 Fat tissue samples (200 mg each) 
were put into a 2­ml Eppendorf ­type tube direct­
ly into 1 ml of the TRI reagent, which contained 
5 μl of the precipitation carrier reagent (MRC 
Inc.). Thereafter, samples were homogenized by 
means of a rotor / stator, hand ­held homogenizer 
(IKA ­Werke GmbH & Co KG, Staufen, Germany). 
All subsequent steps were performed according 
to the manufacturer’s instruction. Finally, puri­
fied RNA was resolved in 100 μl of nuclease ­free 
water. The RNA concentration was determined 
spectrophotometrically by measuring the absor­
bance at 260 nm (BioPhotometer, Eppendorf, 
Hamburg, Germany). A 500 ng of total RNA was 
reverse transcribed using the High ­Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher Sci­
entific, Warsaw, Poland) in a reaction volume of 
20 μl. Finally, the reverse transcription reaction 
mixture was diluted 1:4 with nuclease ­free wa­
ter. A quantitative analysis of the above genes 
was carried out by a 2 ­step real­time reverse tran­
scription–quantitative polymerase chain reaction 
(real ­time RT­qPCR) assay. The human glyceralde­
hyde 3 ­phosphate dehydrogenase gene (GAPDH) 
was used as a reference for quantitative analysis. 
An amount of 2 μl of the reverse transcription re­
action mixture (ie, an equivalent of 10 ng of total 
RNA) was used as a template for RT­qPCR. Real­
­time RT­qPCR was performed using the SYBR Se­
lect Master Mix (Thermo Fisher Scientific) in a to­
tal volume of 20 μl that contained 200 nM of each 
(forward and reverse) gene ­specific primers. All 
primers for RT­qPCR were derived from the Prim­
erBank database (https://pga.mgh.harvard.edu/
primerbank/).19 All primer pairs spanned the in­
tron / exon boundary so this excluded the pos­
sibility of false ­positive results from genomic 
DNA. All primers used are demonstrated in Sup­
plementary material. Reactions were performed 
using the Roche LightCycler 480 Instrument II 
(Roche Diagnostics, Warsaw, Poland) with a ther­
mal profile set as follows: 94 °C/3 min then 35 cy­
cles of 94 °C/30 sec, 58 °C/30 sec, 72 °C/45 sec. 
The specificity of each reaction was confirmed by 
a melting ­curve analysis. The reaction conditions 
for real ­time quantitative PCR were the same for 
all analyzed genes. The increase in fluorescence 
was measured in real time and cycle threshold 
(CT) values were obtained. The target gene CT 
number was normalized to the endogenous ref­
erence GAPDH and the formula 2(­ΔΔCt) was used 
to calculate the relative (to subcutaneous fat [SF]) 
gene expression.20
The above ­mentioned methods were used to 
determine relative mRNA expression of GLP ­1R 
and GLP ­2R as well as RAAS components, that 
is, angiotensin II receptor type 1 (AGTR1), an­
giotensinogen (AGT), angiotensin ­I­converting 
enzyme 1 (ACE1), and angiotensin ­I­converting 
enzyme 2 (ACE2).
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both GLP receptors and the quantity of the cor­
responding fat depots: EF or PF volumes assessed 
in CMR (all P >0.8). Furthermore, the IAT to ASF 
ratio was not associated with the mRNA expres­
sion of GLP ­1R (R = 0.1; P = 0.55) and GLP ­2R 
(R = 0.1; P = 0.4) in PF. Additionally, the APFT to 
ASF ratio was also not associated with GLP ­1R 
(R = 0.2; P = 0.2) and GLP ­2R (r = 0.3; P = 0.07) 
expression in PF.
Renin -angiotensin -aldosterone system receptors 
The relative mRNA expression of ACE1 in EF 
(median [IQR], 0.771 [0.31–1.65]) was lower 
compared with SF (P = 0.002) and similar com­
pared with PF (median [IQR], 0.865 [0.38–2.45]; 
P = 0.5). However, the mRNA expression of ACE2 
showed no differences (all P >0.2) in EF (medi­
an [IQR], 0.818 [0.13–2.63]), PF (median [IQR], 
0.862 [0.15–1.76]) or SF (1.0). The AGT mRNA 
expressions were similar in both EF and PF (me­
dian [IQR], 1.82 [0.34–6.41] vs 1.73 [0.69–4.23]; 
P = 0.9) and significantly higher compared with 
SF (P = 0.04).
Finally, the mRNA expression of AGTR1 was 
lower in EF compared with PF (median [IQR], 
0.58 [0.32–1.47] vs 1.24 [0.72–1.87]; P = 0.01) 
and both showed significant differences com­
pared with SF (both P = 0.02). There were also no 
differences in mRNA expression of RAAS recep­
tors in patients with T2D when compared with 
those without T2D and in patients with BMI of 
30 kg/m2 or greater when compared with those 
with BMI less than 30 kg/m2 (data not shown).
Glucagon -like peptide receptors and renin - angio-
tensin -aldosterone system receptors Both rela­
tive mRNA expression of GLP ­1R and GLP ­2R re­
vealed significant associations with RAAS compo­
nents. GLP ­1R was significantly correlated with all 
assessed RAAS components in EF (AGTR1, AGT, 
ACE1, ACE2) and with: AGTR1, ACE1, and ACE2 
in PF. In turn, GLP ­2R was associated with ACE1 
and ACE2 in PF, and with all assessed RAAS com­
ponent in EF (TAbLE 2). The strongest correlations 
for GLP ­1R were observed with ACE1 in EF and 
PF; and for AGT in PF (all R = 0.5). The expres­
sion of AGTR1 in EF showed the strongest asso­
ciation with GLP ­2R expression. In brief, the as­
sociations between relative mRNA expression of 
GLP receptors and RAAS components were ob­
served for EF as well as for PF depot (TAbLE 2).
dIsCussION Our study evaluated the clinical sig­
nificance of GLP ­1R and GLP ­2R relative mRNA 
expression in EF and PF in relation to the quan­
tity of various thoracic and abdominal fat depots 
and expression of RAAS components in a group 
of patients with a very high cardiovascular risk. 
It was shown that GLP ­1 agonist could have many 
potential beneficial effects on the vascular endo­
thelium, directly improving cardiovascular out­
comes in patients with T2D, for example, an an­
tiproliferative effect on vascular smooth cells and 
endothelial cells, a reduction of oxidative stress, 
TAbLE 1 Clinical characteristics of the study group (n = 53)
Parameter Value
Age, y, mean (SD) 64.7 (7.4)
Male sex 40 (75)
Type 2 diabetes 26 (49)
Dyslipidemia 53 (100)
Total cholesterol, mg/dl, mean (SD) 152 (34)
LDL cholesterol, mg/dl, mean (SD) 86 (29)
HDL cholesterol, mg/dl, mean (SD) 43 (11)
Triglycerides, mg/dl, mean (SD) 119 (50)
Hypertension 53 (100)
Smoker or ex ‑smokera 27 (51)
Risk factorsb, mean (SD) 5.5 (1.4)
Number of vessels with CADc, mean (SD) 2.7 (0.5)
Prior MI 9 (17)
Body mass index, kg/m², mean (SD) 29.9 (4.5)
Overweight / obesity 28 (53) / 21 (39)
Body fat, %, mean (SD) 32.2 (7.7)
WC >80 cm in W or >94 cm in M 42 (79)
WC, cm, mean (SD) 102.4 (12.6)
Metabolic syndrome 30 (56)
Cardiovascular magnetic resonance
Epicardial fat volume, ml, median (IQR) 90.4 (68.1–111.2)
Pericardial fat volume, ml, median (IQR) 121.7 (79.8–168)
Ultrasound
Abdominal subcutaneous fat, mm, mean (SD) 22.7 (9.8)
Abdominal visceral fat, mm, mean (SD) 49 (27)
Abdominal preperitoneal fat, mm, mean (SD) 20.5 (6.4)
Cardiovascular pharmacotherapy
Acetylsalicylic acid 53 (100)
β ‑Blocker 53 (100)





Oral antidiabetic medications 21 (40)
Metformin 11 (20)
Glucagon ‑like peptide‑1 analogues 0
SGLT ‑2 inhibitor 1 (2)
Acarbose 3 (6)
Sulphonylurea 6 (12)
Data are presented as median (interquartile range) or number (percentage) unless 
otherwise indicated.
a Current smoking or smoking in the past for at least 1 year
b Risk factors: male sex, age >55 years old, hypertension, hyperlipidemia, obesity, 
type 2 diabetes, chronic kidney disease, smoking
c Number of coronary arteries with ≥50% stenosis
Abbreviations: ACE I, angiotensin ‑converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; CAD, coronary artery disease; CCB, calcium channel blocker; 
HDL, high ‑density lipoprotein; LDL, low ‑density lipoprotein; M, men; MI, myocardial 
infarction; SGLT ‑2, sodium ‑glucose cotransporter ‑2; W, women; WC, waist 
circumference
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Glucagon -like peptides receptors and epicardial fat 
Iacobellis et al1 were the first to demonstrate 
the presence of GLP ­1R and GLP ­2R expres­
sion in EF. Interestingly, GLP ­2R expression was 
found to be 5 ­fold higher than GLP ­1R.1 Howev­
er, in the immunofluorescence assay, the authors 
showed that GLP ­1R was more abundant in EF 
than SF.1 Contrary, in our study we found that 
only the relative mRNA expression of GLP ­2R was 
lower in SF when compared with SF. Iacobellis et 
al1 found no differences in GLP ­1R and GLP ­2R 
relative expression in EF depots between patients 
with and without T2D, which is similar to our re­
sults. Interestingly, among various medications 
(statins, insulin, thiazolidinediones, dipeptidyl 
peptidase ­4 inhibitors), GLP ­1 analogues were 
evidenced to provide a major reduction in EF vol­
ume.1,25-27 Dozio et al8 showed that GLP ­1R ex­
pression in EF was associated with genes promot­
ing beta ­oxidation, white ­to ­brown adipocyte dif­
ferentiation, and inversely associated with genes 
promoting pro ­adipogenesis. On the other hand, 
GLP ­2R inversely correlated with β­oxidation, and 
was associated with adipogenesis and lipid syn­
thesis genes expression.8 Importantly, GLP ­1R 
and GLP ­2R expressions in EF were higher in pa­
tients with CAD than healthy controls and in pa­
tients with greater EF thickness.8 We used a ref­
erence method of EF quantification (CMR) and 
we found no associations between the expression 
of GLP receptors in fat depot and the volume of 
the depot. GLP ­1R expression in EF was found 
to be lower than GLP ­2R.8 This could be due to 
the down ­regulation of robust cellular activities 
or gene enrichment suppression in subjects with 
chronic CAD.28 Finally, we found similar expres­
sion of both analyzed receptors.
The renin -angiotensin -aldosterone system and epi-
cardial fat The RAAS is a family of peptides with 
proven endocrine and paracrine functions.29 An­
giotensinogen is converted to angiotensin I and 
angiotensin II respectively by 2 enzymes: renin 
and angiotensin ­converting enzyme (ACE).29 
Importantly, angiotensin II is an active peptide 
which is involved in the regulation of blood pres­
sure and fluid balance.29 It was demonstrated that 
increased EF inflammation in an animal model of 
obese mice (lacking ACE2) resulted in worsening 
of insulin resistance and therefore impaired car­
diac metabolism. Those mechanisms were asso­
ciated with increased lipotoxicity and oxidative 
stress.29,30 Moreover, in a rat model after myocar­
dial infarction, the administration of angioten­
sin (1­7) reduced EF inflammation, lipotoxicity, 
and oxidative stress resulting in improved cardi­
ac metabolism and cardiac muscle function.31 It 
was also shown in human EF that the upregula­
tion of ACE2 was associated with obesity and car­
diac dysfunction.30
Glucagon -like peptides and the renin -angiotensin-
-aldosterone system The associations between 
glucagon ­like peptides and the RAAS are mainly 
and an increase in nitric oxide production, re­
sulting in a potential antiatherogenic effect.21,22
Epicardial fat It was demonstrated that athero­
sclerotic plaques in coronary arteries were more 
prevalent in segments surrounded by EF.23,24 Epi­
cardial fat is located directly nearby the myocardi­
um and coronary arteries, so the beneficial effects 
of GLP ­1 activation may extent to the heart.8 It 
has been hypothesized that the proximity of EF 
to the coronary arteries could promote the devel­
opment of atherosclerosis via several para­ and 
endocrine effects.23,24 We have shown previous­
ly that patients with CAD and T2D had an in­
creased volume and more dysfunctional profile 
of gene expression in EF.4 Moreover, those pa­
tients had a significantly decreased expression 
of cardioprotective fibroblast growth factor 21.4 
Therefore, our findings suggest the distinctive 
properties and importance of EF in the progres­
sion of CAD in patients with concomitant T2D.24
FIGuRE 1 The messenger RNA (mRNA) expression of glucagon ‑like peptide ‑1 receptor 
(GLP ‑1R) in subcutaneous, pericardial, and epicardial fat depots: A – relative mRNA 
expression of GLP ‑1R; b – relative mRNA expression of glucagon ‑like peptide ‑2 receptor 
(GLP ‑2R). The values are expressed as relative mRNA expression (subcutaneous fat [SF] 
value used as the reference). The bars represent median values and 95% CI. Difference 
of mRNA expression was compared by the Wilcoxon rank sum test 
Abbreviations: EF, epicardial fat; PF, pericardial fat
SF PF EF 
P = 0.15 
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visceral fat was associated with degree of insu­
lin resistance. The authors showed that subjects 
with obesity and high degree of insulin resistance 
had an increased expression of GLP ­1R in visceral 
fat.36 The potential mechanisms of action of GLP­
­1 analogues are not yet understood, especially in 
terms of impact through fat depots such as EF or 
PF. We provide the first results showing a signif­
icant association between expression of both re­
ceptors in PF (but not EF) and ultrasound mea­
sures of abdominal visceral fat, which is in line 
with the above described findings.
The renin -angiotensin -aldosterone system and oth-
er fat depots Angiotensinogen was found to be 
expressed in fat tissue and secreted by mature 
adipocytes.29,37 Similarly, other components of 
the RAAS, including AGTR1 and ACE2, were also 
expressed in both brown and white fat tissues.29,38 
The AGTR1 and angiotensin II receptor type 2 
may affect angiotensin II both by upregulation 
of the lipogenesis and downregulation of lipoly­
sis.29,39 The local RAAS of the fat tissue was an­
alyzed as a potential contributor to the develop­
ment of systemic insulin resistance.40-42 It was 
demonstrated that angiotensin II produced within 
fat tissues decreased the production of leptin and 
adiponectin, increased free oxygen radicals pro­
duction, and finally induced insulin resistance.42 
Higher values of angiotensin II hampered insu­
lin signaling and increased local oxidative stress 
in the fat samples.43
Other fat depots and cardiovascular risk assessment 
Other fat depots and visceral obesity were also 
found to be linked with the atherosclerosis pro­
cess. We demonstrated that in patients with high 
cardiovascular risk referred to elective coronary 
angiography, the carotid extra ­media thickness, 
an index measure of perivascular adipose tissue, 
was an independent predictor of significant ca­
rotid stenosis.3 It was shown that a combination 
of ultrasound indices related to periarterial fat 
and the vascular wall were associated with more 
based on studies in animal models. In a rodent 
model of polycystic ovary syndrome (PCOS) in 
which cardiometabolic complications are also 
observed, the authors analyzed the association 
of GLP ­1 agonist treatment on mRNA expres­
sion of RAAS components in the kidney tissue.32 
The GLP ­1 agonist decreased renal cortical and 
medullary mRNA expression of RAAS compo­
nents (renin and AGTR1), but only in the control 
group (initially, RAAS components were higher 
in controls compared with PCOS).32 Additional­
ly, a GLP ­1 agonist lowered renal ACE mRNA ex­
pression in the cortex and medulla of the con­
trol group but had no effect in the PCOS group.32
In humans, it was demonstrated that GLP ­1 
blocked the angiotensin II ­induced mesangial 
cell injury and had a beneficial effect in patients 
with diabetic nephropathy.33 Skov et al34 analyzed 
the impact of GLP ­1 infusion using a randomized, 
double ­blind trial on kidney function and RAAS 
components. GLP ­1 administration had no sig­
nificant effect on either glomerular filtration rate 
or renal plasma flow.34 Despite a significant de­
crease in angiotensin II, renin, aldosterone, and 
the angiotensinogen excretion did not change.34
Glucagon -like peptides receptors and other fat depots 
A recent large randomized clinical trial (LEADER 
[Liraglutide Effect and Action in Diabetes: Evalua­
tion of Cardiovascular Outcome Results]) showed 
that GLP ­1 analogues provided significant ben­
efits in reducing cardiovascular mortality, but 
the mechanisms behind this effect remain poor­
ly investigated.9 Ejarque et al35 assessed the ex­
pression of GLP ­1R in subcutaneous and viscer­
al adipose tissue, incretin secretion, glucose ho­
meostasis, and weight loss in patients with mor­
bid obesity and T2D undergoing bariatric surgery. 
The authors showed that GLP ­1R expression in 
adipose tissue was similar independently of T2D 
outcomes and was not linked with weight loss af­
ter bariatric surgery.35 Nevertheless, the GLP ­1R 
expression was higher in visceral fat than in SF.35 
Vendrell et al36 found that GLP ­1R expression in 
TAbLE 2 Glucagon ‑like peptide receptors and the renin ‑angiotensin ‑aldosterone system
RAAS components Glucagon ‑like peptide‑1 receptor Glucagon ‑like peptide‑2 receptor
Spearman rank correlation 
coefficient (R)




Angiotensin II receptor type 1 0.45 0.001 0.3 0.06
Angiotensinogen 0.5 <0.001 0.35 0.2
Angiotensin I–converting enzyme 1 0.5 <0.0001 0.4 <0.01
Angiotensin I–converting enzyme 2 0.4 <0.001 0.5 0.001
Epicardial fat
Angiotensin II receptor type 1 0.35 0.01 0.6 <0.001
Angiotensinogen 0.2 0.2 0.35 0.01
Angiotensin I–converting enzyme 1 0.5 <0.01 0.4 0.02
Angiotensin I–converting enzyme 2 0.4 <0.01 0.45 0.001
Abbreviation: RAAS, renin ‑angiotensin ‑aldosterone system
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clinical indications for cardiac surgery. Thirdly, 
the volume of specimens, especially in lean non­
diabetic individuals, hindered the assessment of 
genes at the protein levels or histological anal­
ysis. Finally, the small number of the analyzed 
group limits the interpretation of comparisons 
between patients with or without obesity and 
with or without T2D.
In conclusion, we demonstrated that GLP ­1R 
and GLP ­2R mRNA expression were associat­
ed with RAAS components assessed in EF and 
PF from patients with severe CAD. Our findings 
suggest the potential role of GLP receptors and 
RAAS components expressed in various fat de­
pots in mediating effects of GLP analogues or 
RAAS inhibitors.
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